• Species Reactivity

  Porcine

• Specificity

  Detects porcine IL-5 in direct ELISAs and Western blots. In direct ELISAs, less than 50% cross‑reactivity with recombinant canine IL‑5 and recombinant feline IL-5 is observed and and less than 30% cross-reactivity with recombinant human IL-5, recombinant mouse IL-5, and recombinant rat IL-5 is observed.

• Source

  Polyclonal Goat IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant porcine IL-5    
  Ile20-Ser134    
  Accession # Q9MYM5

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Endotoxin Level

  <0.10 EU per 1 μg of the antibody by the LAL method.  

• Label

  Unconjugated

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Western Blot

  0.1 µg/mL

  Recombinant Porcine IL‑5 (Catalog # )

• 
  

• Immunocytochemistry

  5-15 µg/mL

  See below

• 
  

• Neutralization

  Measured by its ability to neutralize IL‑5-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T.     et al. (1989) J. Cell Physiol.     140:323. The Neutralization Dose (ND    ₅₀) is typically 2-8 µg/mL in the presence of 25 ng/mL Recombinant Porcine IL‑5.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.2 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-5

Interleukin-5 (IL-5) is a secreted disulfide-linked homodimeric glycoprotein that belongs to the alpha -helical group of cytokines that includes IL-3, IL-5 and GM-CSF (1‑3). IL-5 is primarily produced by CD4⁺ Th2 cells, but eosinophils and mast cells also produce IL-5. Porcine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment (5). Four alpha -helices and two cysteines that form interchain disulfide bonds with a second, antiparallel IL-5 molecule are conserved among species (3 - 5). Monomeric IL-5 is a predicted 14 kDa protein but usage of N-linked glycosylation sites may increase its molecular weight (5). Mature porcine IL-5 shares 90%, 88%, 86%, 85%, 84%, 66%, 68%, 63%, 63% and 59% aa sequence identity with mature bovine, sheep, cat, equine, canine, human, guinea pig, cotton rat, murine and rat IL-5, respectively. Recombinant porcine IL-5 induced proliferation in the human TF-1 cell line (5). The receptor for human IL-5 consists of a 60 kDa ligand-binding subunit (IL-5 R alpha ) and a 120 kDa signal-transducing subunit ( beta _c). It is suggested that dimeric IL-5 binding to IL-5 R alpha recruits beta _c, which subsequently covalently links with IL-5 R alpha. Two receptor complexes then associate to form the physiologic IL-5 receptor (6, 7). IL-5 binds proteoglycans, potentially enhancing its activity (8). Following receptor binding, IL-5 promotes the maturation, activation and migration of eosinophils, as demonstrated during asthmatic eosinophilic lung inflammation (1‑3). It also mobilizes eosinophils and CD34⁺ progenitors from marrow. It also enhances Ig release from B cells and contributes to IL-4 production. Finally, it primes basophils for histamine and leukotriene release (1, 2, 9).

• References:

1. Lalani, T. et al. (1999) Ann. Allergy Asthma Immunol. 82:317.

2. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.

3. Zabeau, L. et al. (2003) Curr. Drug Targets Inflamm. Allergy 2:319.

4. Mertens, B. et al. (1996) Gene 176:273.

5. Sylvin, H. et al. (2000) Immunogenetics 51:59.

6. Bagley, C.J. et al. (1997) Blood 89:1471.

7. Ishino, T. et al. (2005) J. Biol. Chem. 280:22951.

8. Lipscombe, R. et al. (1998) J. Leukocyte Biol. 63:342.

9. Mattes, J. and P.S. Foster (2003) Curr. Drug Targets Inflamm. Allergy 2:169.

• Long Name:

  Interleukin 5

• Entrez Gene IDs:

  3567 (Human); 16191 (Mouse); 24497 (Rat); 397409 (Porcine); 280825 (Bovine); 403790 (Canine); 493803 (Feline)

• Alternate Names:

  BCDF mu; B-cell differentiation factor I; BCGFII; EDF; Eo-CSF; Eosinophil differentiation factor; IL5; IL-5; IL-5T-cell replacing factor; interleukin 5 (colony-stimulating factor, eosinophil); interleukin-5; TRF; TRFB cell differentiation factor I